Cannabis-based medicines for the treatment of tics

For our second episode of "Gilles is in the air", Christelle Nilles co-hosts the interview with Dr Natalia Szejko and together they ask important questions on cannabis-based medicines as a treatment strategy for improving tics.

Our guest today, is Professor Kirsten Müller-Vahl from the Hannover Medical School, specialised in neurology and adult psychiatry. Over the past 30 years, she has investigated Tourette syndrome in more than 3,000 patients.

She is the President of the International Alliance for Cannabinoid Medicines (IACM), and past Chair of the ESSTS.

 

References, studies and papers cited:

• CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. Link
• Abi-Jaoude E, Bhikram T, Parveen F, Levenbach J, Lafreniere-Roula M, Sandor P. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. Cannabis Cannabinoid Res. 2023 Oct;8(5):835-845. doi: 10.1089/can.2022.0091. Epub 2022 Aug 30. PMID: 36040329.
• Mosley PE, Webb L, Suraev A, Hingston L, Turnbull T, Foster K, Ballard E, Gomes L, Mohan A, Sachdev PS, Kevin R, Gordon R, Benson M, McGregor IS. Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome. NEJM Evid. 2023 Sep;2(9):EVIDoa2300012. doi: 10.1056/EVIDoa2300012. Epub 2023 Jun 7. PMID: 38320199.
• Müller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, Fremer C, Weidinger E, Jenz EB, Musil R, Brunnauer A, Großhennig A. The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial. Cannabis Cannabinoid Res. 2024 Jan 23. doi: 10.1089/can.2023.0114. Epub ahead of print. PMID: 38265476.
• Anis S, Zalomek C, Korczyn AD, Lassman S, Rosenberg A, Gurevich T. Licensed Medical Cannabis Use in Gilles de la Tourette Syndrome: A Retrospective Long-term Follow-Up. Cannabis Cannabinoid Res. 2023 May 12. doi: 10.1089/can.2022.0281. Epub ahead of print. PMID: 37172308.